BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19496239)

  • 1. Dasatinib: for some difficult cases of adult leukaemia.
    Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib.
    Kantarjian H; Jabbour E; Grimley J; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Sep; 5(9):717-8. PubMed ID: 17001803
    [No Abstract]   [Full Text] [Related]  

  • 3. Dasatinib (Sprycel) for CML and Ph + ALL.
    Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
    [No Abstract]   [Full Text] [Related]  

  • 4. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
    Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
    Sonmez M; Cobanoglu U; Ovali E; Omay SB
    J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
    [No Abstract]   [Full Text] [Related]  

  • 6. New approved dasatinib regimen available for clinical use.
    Snyder DS
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleural effusions due to dasatinib.
    Brixey AG; Light RW
    Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 9. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
    Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G
    Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
    Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib-induced pleural effusions: a lymphatic network disorder?
    Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
    Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
    Pavlů J; Marin D
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):417-24. PubMed ID: 19951880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
    Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
    Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib-induced lupus.
    Rea D; Bergeron A; Fieschi C; Bengoufa D; Oksenhendler E; Dombret H
    Lancet; 2008 Aug; 372(9640):713-4. PubMed ID: 18761212
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
    Lee SJ; Jung CW; Kim DY; Lee KH; Sohn SK; Kwak JY; Kim HJ; Kim IH; Park S; Kim DH
    Am J Hematol; 2011 Apr; 86(4):346-50. PubMed ID: 21442637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FDA approves new leukemia drug; expands use of current drug.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17338066
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.
    Eskazan AE; Hatemi İ; Öngören Aydın S; Ar MC; Soysal T
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():233. PubMed ID: 25910316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.